The mid-size contract research organization (CRO) sector continues to evolve and surprise experts with rich valuations – and what seems to be a never ending list of transactions.
Eurofins Pharma Bioanalytical Services has launched a consulting program to support clients conducting large molecule preclinical and clinical studies.
Science Exchange has been certified under the EU-US Privacy Shield Framework after completing a seven-step process to demonstrate compliance with various data protection requirements.
Takeda Pharmaceutical Company Limited and Schrödinger Inc. have formed a multi-target research collaboration that leverages Schrödinger’s in silico platform-driven drug discovery capabilities.
SQI Diagnostics Inc. has signed an agreement to commercialize a custom multiplexed assay for a Waltham, MA-based global biotechnology company's blood disorder drug program.
Evotec has joined a consortium through which it gains access to a sample biobank in order to perform drug discovery based on unique kidney disease patient cohorts.
LabCorp’s Covance has opened a new companion diagnostics laboratory as is prepares for an increasing demand for precision medicine – a market expected to reach $112.62bn by 2025.
The global central laboratory and support services provider has secured a $24.5m Series A investment and is on track to double in size, again, over the next five years, says CEO.
This month’s roundup includes new executive leadership teams, hires on both sides of the Atlantic for CRO Smithers Viscient, a new VP and medical director at Clinipace, among others.
Evotec AG has received a payment of approximately €5m ($5.62m) as part of its strategic alliance with Bayer – which the company says is “well on track and very successful.”
AMRI has received a 5-year federal contract award from the National Institutes of Health (NIH) under which it will provide drug substance development and manufacturing services.
Butterworth Laboratories Ltd has secured an additional facility in Hampton, Middlesex as it aims to increase capacity by 60% over the next three years.
The expanded facility features an additional 4,200 square feet of space to enhance its microbiology, sterility testing, and microbial ID service offerings.
NovAliX has signed an insourcing agreement with UCB Biopharma, a model that the CRO says “energizes scientific organization” and offers "significant" cost advantages.
Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.
Genesis Biotechnology Group (GBG) has acquired the preclinical CRO PharmOptima in order to provide customers with a single point-of-contact throughout their drug development programs.
Dubbed LAB282, the £13m (€15M) Oxford University drug discovery program with Evotec has announced two grant winners and a second set of awards of up to £250,000.
The Research Institute for Chromatography (RIC) and Anacura have joined forces to create anaRIC biologics, an R&D and GMP analytical specialist CRO for biologics.
Charles River Laboratories International Inc. has sold off its CDMO business QS Pharma LLC, saying the small-molecule manufacturing business was “not optimized” within the firm's portfolio.
A US-subsidiary of the Chinese CDMO Porton Fine Chemicals Ltd. has bought the New Jersey based small molecule API contract research organisation, J-STAR Research, Inc.
Amatsigroup has acquired single-use processing equipment and packaging tech firm Disposable-Lab SAS as part of a plan to increase its revenue to €50m this year.
Bruker has bolstered its molecular biologics and mass spectrometric offering through the acquisition of contract manufacturing organisation (CMO) InVivo Biotech.
NanoTemper Technologies Gmbh has scored custom from the UK CRO Domainex Ltd., which is using its MicroScale Thermophoresis technology for speedier, “higher quality clinical candidates”.
With several systems and process improvement initiatives underway, the growing contract research organization (CRO), Venn Life Sciences, continues to look for earnings enhancing opportunities, says CEO.
BioPharma Services has acquired intellectual property and human resource assets from Bioanalytical Laboratory Services (BLS), including a list of validated assays.
Potentially hazardous bio-waste generated at the UK National Biologics Manufacturing Centre (NBMC) in Darlington is being made safe using a bespoke system developed by Suncombe.
Pharma is looking to condense the number of contract manufacturers it works with, says Aesica which has launched a service to help manage its customers’ supply chain.
Full spectrum CROs are well-positioned to service the growing demand for late-stage observational trials driven by regulatory and patient pressure, says Quintiles.